Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) headquartered in Waltham, will host a conference call for the investment community to discuss the 3Q20 financial results on 5th November 2020 at 4:30 PM Eastern Time.
The conference call will also be webcast live under the investor relations section of the website www.eloxxpharma.com
Earnings Expectation
Eloxx Pharmaceuticals, Inc. is reporting third quarter financial results on Thursday 5th November 2020, after market close.
According to analysts surveyed by Thomson Reuters, ELOX is expected to report 3Q20 loss of $ 0.19 per share. For the full year, analysts anticipate loss of $ 0.95 per share bottom line.
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops novel ribonucleic acid for the treatment of rare and ultra-rare premature stop codon diseases. Its lead program is ELX-02, which has completed Phase 1 clinical trial that focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations. The company was founded in 2013 and is headquartered in Waltham, Massachusetts.
